Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

Overactive Bladder Clinical Trial

Official title:

A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01729819
• Other study ID #: 000085
• Status: Completed
• Phase: Phase 2
• Start date: January 2013
• Est. completion date: November 2014

Study information

• Verified date: August 2018
• Source: Ferring Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent prior to performance of any trial-related activity

• Female sex, at least 18 years of age (at the time of written consent)

• Nocturia and overactive bladder symptoms present for =6 months prior to trial entry (patient-reported)

• At least 2 nocturnal voids each night as documented in 2 diary periods during the screening. A mean of at least 8 daytime voids per day over 3 days with a minimum of at least 6 daytime voids each day as documented in 2 diary periods during the screening. At least 1 urgency episode each 24 hours as documented in 2 diary periods during the screening. Each diary period consists of 3 consecutive days, with at least 14 days between each period.

Exclusion Criteria:

• Evidence of severe voiding dysfunction defined as:

More than 10 nocturnal voids per 24 hours as documented on any of the days in both diary periods during screening.

More than 20 daytime voids per 24 hours as documented on any of the days in both diary periods during screening.

• Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder related pain, or stone in the bladder and urethra causing symptoms

• Current or a history within 5 years of lower urologic malignancies (e.g., bladder cancer), lower urinary tract surgery, previous pelvic irradiation, or severe neurological disease affecting bladder function or muscle strength (e.g., multiple sclerosis, Parkinson's disease, spinal cord injury, spina bifida)

• Symptoms of severe stress urinary incontinence in the opinion of the investigator

• Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention

• Habitual or psychogenic polydipsia (fluid intake resulting in a urine production exceeding 40 mL/kg/24 hours) or a mean volume voided per void of 350 mL or more during one or more 24-hour periods as assessed by the screening diaries

• Central or nephrogenic diabetes insipidus

• Syndrome of inappropriate antidiuretic hormone (SIADH)

• Gastric retention

• Myasthenia gravis

• Uncontrolled narrow-angle glaucoma

• Suspicion or evidence of cardiac failure

• Uncontrolled and clinically relevant (in the judgement of the investigator) hypertension or diabetes mellitus

• History and/or current treatment of obstructive sleep apnoea

• Hyponatraemia:Serum sodium level must not be below 135 mmol/L

• Evidence of potential renal impairment:Serum creatinine must be within normal laboratory reference intervals AND estimated glomerular filtration rate must be more than or equal to 50 mL/min

• Hepatic and/or biliary diseases: Aspartate aminotransferase and/or alanine aminotransferase levels must not be more than twice the upper limit of normal range. Total bilirubin level must not be more than 1.5 mg/dL

• Pregnancy, breastfeeding, or a plan to become pregnant during the period of the trial. Women of reproductive age must have documentation of a reliable method of contraception. All pre- and perimenopausal women have to perform pregnancy tests. Amenorrhea of more than 12 months duration based on the reported date of the last menstrual period is sufficient documentation of post-menopausal status and does not require a pregnancy test

• Known alcohol or substance abuse; work or lifestyle that may interfere with regular night-time sleep e.g., shift workers; or any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, illiteracy or language barrier which, in the judgement of the investigator, would impair participation in the trial

• Known or suspected hypersensitivity to any active ingredient or excipients in the investigational medicinal products used in the trial

• Previous participation in any desmopressin trial within the last 5 years

• Use of any prohibited therapy, as defined in the protocol

Related Conditions & MeSH terms

• Nocturia
• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Drug:
• Tolterodine tartrate extended release capsules

• Desmopressin orally disintegrating tablets

• Placebo orally disintegrating tablets

Locations

Country	Name	City	State
United States	The Urological Institute of Northeastern New York	Albany	New York
United States	Parkhurst Research Organization, LLC	Bethany	Oklahoma
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Research Across America	Dallas	Texas
United States	Riverside Clinical Research	Edgewater	Florida
United States	Northshore Center for Gastroenterology	Evanston	Illinois
United States	Advances in Health	Houston	Texas
United States	Pioneer Research Solutions, Inc.	Houston	Texas
United States	NEA Baptist Clinic	Jonesboro	Arkansas
United States	Health Awareness, Inc.	Jupiter	Florida
United States	Lynn Institute of The Ozarks	Little Rock	Arkansas
United States	Moez Khorsandi, DO	Los Angeles	California
United States	Urology Group of Southern California	Los Angeles	California
United States	Coastal Carolina Research Center	Mount Pleasant	South Carolina
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Clinical Research Associates of Tidewater	Norfolk	Virginia
United States	Pines Clinical Research, Inc.	Pembroke Pines	Florida
United States	Philadelphia Clinical Research, LLC	Philadelphia	Pennsylvania
United States	Premier Medical Group of the Hudson Valley, P.C.	Poughkeepsie	New York
United States	Remedica, LLC	Rochester	Michigan
United States	Radiant Research	San Antonio	Texas
United States	Seattle Women's: Health, Research, Gynecology	Seattle	Washington
United States	Clinical Research Atlanta	Stockbridge	Georgia
United States	Palm Beach Research Center	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Mean Number of Nocturnal Voids From Baseline	A nocturnal void was defined as a void occurring at least 5 minutes after going to bed, but before getting up the next morning. The mean estimate was the average over 3 consecutive 24-hour periods prior to the respective visit as captured in the voiding and sleep diary.	Baseline to 3 months of treatment
Secondary	Change in Mean Time to First Nocturnal Void From Baseline	The time to first nocturnal void was defined as the time from going to bed with the intention of sleeping until first nocturnal void or until waking in the morning in the case there is no nocturnal void. The time to first void was calculated as the average over three consecutive 24-hour periods prior to the respective visits.	Baseline to 3 months of treatment
Secondary	Change in Mean Nocturnal Urine Volume From Baseline	The mean nocturnal urine volume was derived from the three-day urine volume diary. The nocturnal volume was defined as the sum of the volumes for all nocturnal voids including the volume of the first morning void within 30 min of waking up in the morning.	Baseline to 3 months of treatment
Secondary	Responder Status	Responder status was defined as =33% decrease in the mean number of nocturnal void and at least one night with no voids out of the 3-day diary period.	Baseline to 3 months of treatment
Secondary	Onset of Effect as Seen in Change in Mean Number of Nocturnal Voids From Baseline for Each Visit During Three Months of Treatment	A nocturnal void was defined as a void occurring at least 5 minutes after going to bed, but before getting up the next morning. The mean estimate was the average over 3 consecutive 24-hour periods prior to the respective visit as captured in the voiding and sleep diary.	Baseline to 3 months of treatment
Secondary	Change in the Impact on Sleep as Measured by the Sleep Rating Scales From Baseline	An electronic diary was used in the trial to document the impact on sleep quality (sleep rating scales). The sleep rating scales included three questions that ranged from 0 (poor) to 10 (good). The average of each question for each visit was summarised and the change from baseline was analysed longitudinally during the three months of treatment.	Baseline to 3 months of treatment